Advertisement

---

ENDO HEALTH SOLUTIONS INC.

Endo Health Solutions Announces Actions To Streamline Operations And Expand Platform For Sustainable Cash Flow And Earnings Growth

[2013-06-05] - -- Restructuring Expected To Reduce Annual Operating Expenses By $325 Million
-- Exploring Strategic Alternatives For HealthTronics Business and Branded Pharmaceutical Discovery Platform
-- Will Focus On Organic Growth, More Efficient R&D Spend, Disciplined Capital Allocation
-- Company Updates 2013 Guidance: Expects Revenues Of $2.65 Billion To $2.80 Billion; Adjusted Diluted EPS Of $4.10 To $4.40; GAAP EPS Of $1.49 To $1.79


Endo Pharmaceuticals Provides Regulatory Update On AVEED™ (Testosterone Undecanoate) Injection

[2013-05-30] -


Endo Health Solutions Announces Departure of Chief Operating Officer

[2013-05-29] -


Endo Health Solutions Announces Departure Of Chief Financial Officer

[2013-05-29] -


Endo Health Solutions Responds to FDA's Denial of OPANA® ER Citizen Petition and the Potential Approval of Additional Non-Abuse Deterrent Formulations of Generic Oxymorphone

[2013-05-10] -


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers